Rakovina highlighted the development of its kt-3000 drug candidates as a potential treatment of Ewing sarcoma and other soft tissue tutors..

FDA has granted the request for a meeting to review the clinical trial protocol for its Phase 3 study in high-risk COVID-19 outpatients.

The CPP brings together businesses, policy makers, and NGOs to work together and create a national solution to plastic waste and pollution..

The data presented suggested promising activity for bi-functional kt-4000 series compounds...

Rakovina’s presentation will highlight the development of its drug candidates as a potential treatment of sarcomas and soft tissue tumors..

he article outlines the positive impact of apabetalone in the investigator-led pulmonary arterial hypertension (PAH) pilot study, APPRoAcH-p

Rakovina Therapeutics presentation will highlight pre-clinical research related to its novel kt-4000 series.